Skandinaviska Enskilda Banken Ab (Publ) Coherus Bio Sciences, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$14.42 - $21.39 $1.64 Million - $2.43 Million	-113,700 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$16.56 - $18.94 $354,384 - $405,316	21,400 Added 23.19%	113,700 $1.98 Million
Q3 2020 Nov 12, 2020	BUY	$17.41 - $19.89 $809,565 - $924,885	46,500 Added 101.53%	92,300 $1.69 Million
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $660,894 - $877,528	45,800 New	45,800 $818,000

134

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $114M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.